Representative Kim Schrier (D-WA) has been officially designated as the incoming Democratic co-chair of the Congressional Diabetes Caucus, marking a significant transition in leadership for one of the largest and most influential bipartisan organizations in the United States House of Representatives. Representative Schrier is slated to succeed Representative Diana DeGette (D-CO) when the 119th Congress convenes in January 2027. This change in leadership follows the recent election cycle in which Representative DeGette lost her bid for re-election, concluding a long and storied tenure as a primary advocate for diabetes research and patient protections. Representative Gus Bilirakis (R-FL) will remain in his role as the Republican co-chair, ensuring continuity in the caucus’s tradition of bipartisan cooperation on public health issues.
The appointment of Representative Schrier is viewed by many in the medical and advocacy communities as a natural progression for the caucus. As the only pediatrician currently serving in Congress and the only member living with type 1 diabetes, Schrier brings a unique combination of clinical expertise and personal lived experience to the role. Diagnosed with type 1 diabetes at the age of 16, she has spent her professional life both treating patients and navigating the complexities of the American healthcare system as a chronic disease patient. Her elevation to this leadership position signals a potential shift toward a more clinically focused approach to federal diabetes policy.
A Legacy of Bipartisan Advocacy: The Congressional Diabetes Caucus
The Congressional Diabetes Caucus, founded in 1996, has grown to become one of the largest caucuses in the House, frequently boasting more than 300 members from both sides of the aisle. Its primary mission is to educate members of Congress and their staff about diabetes and to support legislation that improves diabetes research, education, and treatment. The caucus serves as a critical bridge between the legislative branch and the scientific community, working closely with organizations such as the Endocrine Society, the American Diabetes Association (ADA), and JDRF (formerly the Juvenile Diabetes Research Foundation).
The outgoing co-chair, Representative Diana DeGette, has been a cornerstone of the caucus for over two decades. Her leadership was instrumental in the passage of several landmark pieces of legislation, including the multi-year renewals of the Special Diabetes Program (SDP) and various initiatives aimed at curbing the rising cost of insulin. Her departure marks the end of an era for the caucus, but the transition to Representative Schrier suggests a continuation of the aggressive advocacy that has defined the group’s history.
Representative Gus Bilirakis, who will continue to lead the caucus from the Republican side, has maintained a strong partnership with his Democratic counterparts. This bipartisan synergy is essential in a divided Congress, particularly when addressing issues that require long-term funding commitments, such as federal research grants and Medicare coverage expansions.
The Professional and Personal Background of Representative Kim Schrier
Representative Schrier’s background provides her with a perspective that is rare in the halls of Congress. Before her election to the House in 2018, she spent 17 years as a pediatrician in Issaquah, Washington. In her clinical practice, she worked directly with families managing both type 1 and type 2 diabetes, witnessing firsthand the barriers to care, including the high costs of medical technology and the life-saving medication insulin.
Her personal diagnosis at age 16 serves as a foundational element of her legislative identity. Type 1 diabetes is an autoimmune disease in which the pancreas produces little or no insulin, requiring patients to rely on external insulin delivery via injections or pumps for the rest of their lives. By bringing this personal history to the co-chair position, Schrier is expected to prioritize the issues of "patient-centered care" and "technological accessibility."
In previous legislative sessions, Schrier has been a vocal proponent of the "INSULIN Act," which sought to cap out-of-pocket costs for insulin and address the opaque pricing structures of Pharmacy Benefit Managers (PBMs). Her dual identity as a physician and a patient allows her to speak with authority on the physiological necessity of insulin and the economic devastation that occurs when patients are forced to ration their doses.
The Economic and Public Health Burden of Diabetes in the United States
The leadership transition comes at a time when the prevalence of diabetes in the United States has reached record levels, placing an unprecedented strain on the national healthcare infrastructure. According to the most recent data from the Centers for Disease Control and Prevention (CDC), approximately 38.4 million Americans—about 11.6% of the population—have diabetes. Furthermore, an estimated 97.6 million adults aged 18 or older have prediabetes, a condition that significantly increases the risk of developing type 2 diabetes, heart disease, and stroke.
The financial implications of the epidemic are staggering. A 2023 study commissioned by the American Diabetes Association found that the total estimated cost of diagnosed diabetes in the U.S. rose to $412 billion in 2022, including $306 billion in direct medical costs and $106 billion in indirect costs, such as reduced productivity and disability. People with diagnosed diabetes now account for one in every four healthcare dollars spent in the U.S., and more than half of those expenditures are directly attributable to the disease.
For the Congressional Diabetes Caucus, these numbers represent a call to action. The caucus focuses heavily on the "Special Diabetes Program" (SDP), which consists of two components: the Special Statutory Funding Program for Type 1 Diabetes Research at the National Institutes of Health (NIH) and the Special Diabetes Program for Indians (SDPI). Since its inception in 1997, the SDP has received bipartisan support, but it requires periodic reauthorization. Ensuring the long-term stability of this funding will be one of the first major challenges for the Schrier-Bilirakis leadership team in 2027.
Legislative Priorities and the Role of the Endocrine Society
The Endocrine Society, a global professional organization representing thousands of physicians and scientists, has expressed strong support for the leadership change. The Society has maintained a longstanding partnership with the caucus, providing expert testimony and data to inform policy decisions. In a statement regarding the appointment, the Society emphasized its commitment to working with Representative Schrier on a wide range of issues impacting endocrinologists and their patients.
Among the top priorities identified by the Society and the caucus for the upcoming 119th Congress are:
- Insulin Affordability: While the Inflation Reduction Act of 2022 successfully capped insulin costs at $35 per month for Medicare beneficiaries, millions of Americans with private insurance or no insurance at all remain vulnerable to high prices. The caucus is expected to push for a universal cap that extends to the commercial market.
- Special Diabetes Program (SDP) Funding: The SDP is credited with breakthroughs in continuous glucose monitoring (CGM) technology and artificial pancreas systems. Advocacy groups are pushing for a significant increase in annual funding to keep pace with inflation and the rising costs of clinical trials.
- Modernizing Medicare Coverage: There is an ongoing effort to ensure that Medicare coverage keeps pace with technological innovations, such as smart insulin pens and advanced data-sharing platforms that allow endocrinologists to monitor patients remotely.
- Addressing Health Disparities: Data indicates that diabetes disproportionately affects minority communities and rural populations. The caucus aims to expand the National Diabetes Prevention Program (National DPP) to reach these underserved areas.
Chronology of Federal Diabetes Policy and Future Outlook
The history of federal diabetes policy has been characterized by incremental progress. In the late 1990s, the focus was primarily on establishing a dedicated research budget. By the 2010s, the conversation shifted toward the "insulin crisis," as the list price of the drug tripled over a decade. In recent years, the emphasis has expanded to include the "Total Cost of Care" model, which looks at how preventing complications—such as kidney failure, blindness, and amputations—can save the federal government billions in long-term Medicare and Medicaid spending.
The transition from Representative DeGette to Representative Schrier represents a shift from the veteran "policy architect" to the "practitioner-legislator." While DeGette was instrumental in drafting the legal frameworks that govern medical research, Schrier is expected to focus on the practicalities of the patient experience. Her medical background will likely lead to a greater emphasis on pediatric diabetes and the transition of care as young patients move into adulthood.
As the 119th Congress approaches, the Congressional Diabetes Caucus remains a rare bastion of bipartisanship in a polarized political climate. The shared goal of eradicating diabetes and easing the burden for those living with the condition continues to unite lawmakers. With Representative Schrier at the helm alongside Representative Bilirakis, the medical community anticipates a period of vigorous legislative activity aimed at moving the needle on research, affordability, and ultimately, a cure.
The Endocrine Society and other stakeholder groups have signaled their readiness to assist the new co-chair in her transition. "We are grateful to Representative DeGette for her leadership and accomplishments on diabetes issues during her time in Congress," the Society noted, while expressing confidence that Representative Schrier’s "important contributions to legislation" will lead to better prevention and treatment outcomes for the millions of Americans affected by the disease. As January 2027 nears, the focus will remain on ensuring that the momentum built over the last three decades is not lost during this change in leadership.
